PSORIATIC ARTHRITIS NEWS AND VIEWS
VOLUME- 4 ISSUE- 17
November 30, 2004
PSORIATIC ARTHRITIS MEDICAL NEWS
BEE VENOM MAY SOOTHE RHEUMATOID ARTHRITIS
Blocks genes that cause tissue swelling, study says
By Janice Billingsley - HealthDay Reporter
(HealthDayNews) -- While bee venom has been touted for many years as an
analgesic for arthritis sufferers, a new study has discovered just how it might
work to make people feel better.
In animal studies conducted last year, doctors in South Korea found that
melittin, the principal peptide in bee venom, blocks the expression of
inflammatory genes that can cause painful tissue swelling in rheumatoid
arthritis
patients.
"The potency of melittin in the inhibition of the inflammatory response may
be of great benefit in degenerative and inflammatory diseases such as
rheumatoid arthritis," the authors wrote in their study, which appears in the
November issue of Arthritis and Rheumatism.
For the study, researchers first studied rats treated to induce inflammatory
arthritis. For rats with advanced rheumatoid arthritis, low doses of bee
venom dramatically reduced tissue swelling as well as abnormal bony growth
caused by the disease.
Next, researchers tested the anti-inflammatory effects of melittin on human
synovial cells of arthritis patients. Synovial cells are those that line the
joints, and which are vulnerable to inflammation among arthritis sufferers.
They found the melittin blocked the expression of the genes that cause the
inflammation and pain suffered by arthritis patients. The melittin worked in a
similar way to a class of drugs called cox-2 inhibitors, which are now used
to treat rheumatoid arthritis and reduce inflammation, the scientists wrote.
The melittin also reduced the amount of nitric oxide in the synovial cells,
the researchers found. This has potential palliative effects as well, because
there is evidence that tissues affected by inflammatory arthritis produce
large amounts of nitric oxide.
"Although further study is needed for determination of an effective dose,
our data show that the anti-arthritic effects of bee venom are related to its
anti-inflammatory effects," the authors wrote.
"This is an interesting study. The authors are claiming that bee venom
actually causes a reduction in inflammatory response, which is counterintuitive,
because a bee sting causes severe local inflammation, with swelling and edema,"
said Raymond Dingledine, chairman of the department of pharmacology at
Atlanta's Emory School of Medicine.
Dingledine said it has been thought that the reason bee venom, which has
been a folk medicine for arthritis for a long time, might have a soothing effect
on arthritis is because when stung by a bee, the body produces cortisone to
fight the local inflammation, and it was thought that the increase in
cortisone could be easing the swelling of other tissue affected by arthritis.
But he said there haven't been controlled clinical trials to determine
whether there really is a benefit, for the very practical reason that bee stings
"hurt like crazy" and a study would have to create a placebo that would be
equally painful.
Also, he added, there are other medications for arthritis (like nonsteroidal
anti-inflammatory drugs), as well as surgery, exercise and diet.
"However, there are people for whom standard treatments don't work, and this
is a new idea for how bee venom might have anti-inflammatory advantages," he
said.
Rheumatoid arthritis, a chronic disease and potentially debilitating disease
mainly characterized by inflammation of the lining of the joints, affects
approximately 2.1 million people in the United States, primarily women,
according to the Arthritis Foundation.
SOURCES: Raymond Dingledine, Ph.D., chairman, Department of Pharmacology,
Emory School of Medicine, Atlanta; November 2004 Arthritis & Rheumatism
Copyright © 2004 ScoutNews LLC. All rights reserved.
***********************************************************
DRUG COMBO BETTER FOR RHEUMATOID ARTHRITIS
Two medications better than one, researchers say
The Associated Press
LONDON - Combining a new drug with the standard initial treatment for
rheumatoid arthritis seems to work better than using either medicine alone,
research indicates.
About 1 percent of people have rheumatoid arthritis, a crippling disease in
which the immune system goes awry and attacks the joints.
For nearly two decades, the standard drug against the disease has been
methotrexate, originally developed to fight cancer. But two out of three
patients
donât respond well to it.
Enbrel targets inflammation-causing protein
The newer drug, Enbrel, belongs to a class of medicines that target an
inflammation-causing protein called tumor necrosis factor, or TNF. Such drugs
have
helped people who have not benefited from methotrexate.
The new study, outlined this week in The Lancet medical journal,
investigated for the first time whether giving both drugs from the onset would
be better
than using one alone. Conducted by experts at the Karolinska Institute in
Stockholm, Sweden, it involved 682 patients who were given either one of the
two drugs or both.
A year after treatment began, 35 percent of the patients in the combination
group were in remission, compared with 13 percent of those on methotrexate
alone and 16 percent of those on Enbrel alone.
There was no further deterioration of joints in 80 percent of patients on
combination treatment, compared with 68 percent on methotrexate and 57 percent
on Enbrel alone.
Dr. Armin Schnabel of the Rheumatology and Immunology Clinic in Bad Wildbad,
Germany, said that although the results show the combination treatment is
better, therapy for rheumatoid arthritis remains imperfect.
âEfficacy can be enhanced by combining (Enbrel) and methotrexate from the
beginning, but even the combination leaves a sizable number of patients with
active inflammation,â said Schnabel, who was not connected with the research.
The Lancet study involved people who had suffered from the disease for a
long time. Perhaps aggressive combination treatment early in the course of the
disease could make a big difference in switching off the destruction caused by
inflammation, he said. The study was funded by Wyeth, the company that makes
Enbrel.
© 2004 The Associated Press. All rights reserved.
*****************************************************************
REMICADE IN EUROPE
Europe Recommends Approval of Remicade (Infliximab) for Treatment of
Psoriatic Arthritis
(My thanks once again to our roving reporter from the United Kingdom -
Michael Szczygiel.)
KENILWORTH, NJ -- August 2, 2004 -- Schering-Plough Corporation announced
that the Committee for Medicinal Products for Human Use (CHMP) of the European
Agency for the Evaluation of Medicinal Products (EMEA) has issued a positive
opinion recommending approval of expanded labeling for Remicade(r)
(infliximab), in combination with methotrexate, for treatment of active and
progressive
psoriatic arthritis (PsA) in patients who have responded inadequately to
disease modifying anti- rheumatic drugs (DMARDs). Psoriatic arthritis is a
chronic autoimmune inflammatory condition involving the joints and the skin.
The positive opinion for Remicade as a treatment for PsA is primarily based
on data from IMPACT (Infliximab Multinational Psoriatic Arthritis Controlled
Trial)(1), a randomized, double-blind, placebo-controlled study involving 104
patients with active PsA who had failed at least one DMARD and were enrolled
at nine centers in the United States, Canada and Europe. Results
demonstrated the safety and efficacy of Remicade in treating this
debilitating disorder.
In IMPACT, patients given Remicade (5mg/kg) experienced rapid and sustained
improvement in their joints, as measured by the ACR 20, 50 and 70 response
criteria, measurement tools used to assess disease activity and improvement.
Specifically, 34 of the 52 patients (65.4 percent) met the ACR 20 response
criteria -- the primary efficacy parameter -- at week 16, compared to five of
the
52 patients (9.6 percent) in the placebo group. Responses were sustained
through the end of the study (week 50). Results were confirmed in the ACR 50 and
ACR 70 scores among those treated with Remicade: 24 patients
(46.2 percent) met the ACR 50 response at week 16 with 26 patients (53.1
percent) meeting it at week 50; 15 patients (28.8 percent) met the ACR 70
response at week 16, with 19 patients (38.8 percent) meeting it at week 50.
The CHMP recommendation serves as the basis for a European Commission
approval. A Commission approval of the application will result in Marketing
Authorization with unified labeling that will be valid in all EU-Member states,
including the current 15 member states and the 10 new accession countries as
well
as in Iceland and Norway.
The Arthritis Research Campaign estimates 1 in 50 people have psoriasis. Of
these, about 1 in 14 will develop PsA. (2) While PsA can develop at any age,
onset usually occurs in middle age, typically in adults between the ages of 30
and 50. Men and women are affected equally. Symptoms include stiffness,
pain, swelling and tenderness of the joints and surrounding soft tissue,
reduced range of motion, morning stiffness, and tiredness. Other symptoms
include nail changes, including pitting (small indentations in the nail) or
lifting of the nail.
Remicade is a monoclonal antibody that specifically targets and irreversibly
binds to TNF-alpha which has been shown to play a role in RA, CD, AS and
psoriasis, and may also be important in a wide range of other immune- mediated
inflammatory disorders. Remicade is unique among available anti-TNF biologic
therapies. Unlike self-administered therapies that require patients to inject
themselves frequently, Remicade is the only anti-TNF biologic administered
directly under supervision and monitoring of specialized physicians. In RA and
CD patients, Remicade is administered every eight weeks, following a standard
induction regimen that requires treatment at weeks 0, 2 and 6. As a result,
Remicade patients may require as few as six treatments each year. The safety
and efficacy of Remicade have been well established in clinical trials
conducted over the past 10 years and through commercial experience with more
than
500,000 patients treated worldwide.
Remicade is the only biologic indicated for the treatment of both RA and
Crohn's disease (CD), a serious gastrointestinal disorder. In the EU, Remicade
is also approved for the treatment of Ankylosing Spondylitis (AS), a serious
inflammatory disease that leads to stiffening and subsequent fusion of the
spine.
For RA patients, Remicade, in combination with methotrexate, is indicated
for the reduction of signs and symptoms as well as the improvement in physical
function in patients with active disease when the response to disease-
modifying drugs, including methotrexate, has been inadequate, and in patients
with
severe active and progressive disease not previously treated with methotrexate
or other DMARDS. In these patient populations, a reduction in the rate of
the progression of joint damage, as measured by X-ray, has been demonstrated.
In CD patients, Remicade is indicated for the treatment of severe, active
Crohn's disease in patients who have not responded despite a full and adequate
course of therapy with a corticosteroid and an immunosuppressant; or who are
intolerant to or have medical contraindications for such therapies. Remicade
is also indicated for the treatment of fistulizing, active Crohn's disease in
patients who have not responded despite a full and adequate course of therapy
with conventional treatment (including antibiotics, drainage and
immunosuppressive therapy).
In the EU, Remicade is also indicated for treatment of ankylosing
spondylitis in patients who have severe axial symptoms, elevated serological
markers of
inflammatory activity and who have responded inadequately to conventional
therapy.
Important Information Regarding Labeling for Remicade
People with heart failure should not take Remicade. Prior to treatment,
patients should discuss any heart condition with their doctor. Patients should
tell their doctor immediately if they develop new or worsening symptoms of
heart failure (such as shortness of breath or swelling of feet). There are
reports of serious infections associated with Remicade therapy, including
tuberculosis (TB) and sepsis. Some of these infections have been fatal.
Patients
should tell their doctor if they have had recent or past exposure to people
with
TB. Their doctor will evaluate them for TB. If a patient has latent (inactive)
TB, his or her doctor should begin TB treatment before starting Remicade. If
a patient is prone to or has a history of infections, currently has one, or
develops one while taking Remicade, he or she should tell his or her doctor
immediately. Patients should also tell their doctor if they have or have had a
disease that affects the nervous system, or if they experience any numbness,
tingling or
visual disturbances. There are also reports of serious infusion reactions
with hives, difficulty breathing and low blood pressure. In clinical studies,
some people experienced the following common side effects: upper respiratory
infections, headache, nausea, cough, sinusitis or mild reactions to the
infusion such as rash or itchy skin. Please read important
information about Remicade, including full U.S. prescribing information at
_http://www.remicade.com_ (http://www.remicade.com) .
For complete Remicade EU prescribing information, call Schering-Plough
Corporation at +1 908-298-7616.
*******************************************************
U.S. FUTURE FULL OF FRACTURES
Unless Americans start getting enough calcium, vitamin D and physical
activity, their future is likely to include osteoporosis accompanied by a lot of
broken bones. This is the gist of a report by the US Surgeon General entitled
Bone Health and Osteoporosis The full report is more than 400 pages long and
took two years to prepare.
This comprehensive report makes a dire prediction -- that by the year 2020,
one in two Americans over age 50 will be at risk for fractures from
osteoporosis or low bone mass. Ten million Americans already do have
osteoporosis. Many
don't discover that they have osteoporosis until they experience an
unexpectedly broken bone.
The Surgeon General's report tries to dispel myths associated with
osteoporosis. For example, the segment of the population suffering from
osteoporosis
or other bone disease is NOT small, osteoporosis is NOT only a problem for
older white women, diagnosing osteoporosis is NOT a lengthy and painful
process,
osteoporosis is NOT unresponsive to treatment, and osteoporosis CAN be
prevented in the first place
In order to make sure that all the information contained in the report is
readily available to the general public, there is not only a free pamphlet
entitled The 2004 Surgeon General's Report on Bone Health and Osteoporosis. What
it Means To You, but 4 different fact sheets and even a streaming video
entitled Osteoporosis in the Family.
Comment: Many of us know of situations in our own families where
osteoporosis has had serious consequences. An uncle who broke his hip when he
slipped on
a wet sidewalk while getting the morning newspaper, a mother whose COPD
worsened as her spinal column compressed and her rib cage collapsed, a
stepmother
who could not walk because it became impossible to surgically repair and
re-repair her osteoporotic hips. All of these family members might have lived
longer if their osteoporosis had been diagnosed and aggressively treated at an
earlier age. Certainly, their quality of life in their final years would have
been greatly improved. Barbara K. Hecht, Ph.D., Frederick Hecht, M.D.,
Medical Editors, MedicineNet.com
BY 2020, ONE IN TWO AMERICANS OVER AGE 50 WILL BE AT RISK FOR FRACTURES FROM
OSTEOPORIS OR LOW BONE MASS
The Surgeon General issues first-ever report on nation's bone health
U.S. Surgeon General Richard H. Carmona, M.D., M.P.H., F.A.C.S., warned
today in a new report that by 2020, half of all American citizens older than 50
will be at risk for fractures from osteoporosis and low bone mass if no
immediate action is taken by individuals at risk, doctors, health systems, and
policymakers. This new report, "Bone Health and Osteoporosis: A Report of the
Surgeon General" says that 10 million Americans over the age of 50 have
osteoporosis, the most common bone disease, while another 34 million are at risk
for
developing osteoporosis. And each year, roughly 1.5 million people suffer a
bone fracture related to osteoporosis.
This report is the first-ever Surgeon General's report on the topic of bone
health. Osteoporosis and other bone diseases, such as Paget's disease and
osteogenesis imperfecta can lead to a downward spiral in physical health and
quality of life, including losing the ability to walk, stand up, or dress, and
can lead to premature death.
"This report will shape the way we approach, talk, and act about bone
diseases," HHS Secretary Tommy G. Thompson said. "The more we learn, the more we
realize that so many diseases are preventable, from obesity, to many types of
cancer, and now bone disease. I want to thank Dr. Carmona and all the
scientists and researchers who worked on this report. I look forward to the
impact
this new information will make in the health of communities."
Other findings in the report include:
About 20 percent of senior citizens who suffer a hip fracture die within a
year of fracture.
About 20 percent of individuals with a hip fracture end up in a nursing home
within a year.
Hip fractures account for 300,000 hospitalizations each year.
The direct care costs for osteoporotic fractures alone are already up to $18
billion each year. That number is expected to increase if action to prevent
osteoporosis is not taken now.
"Osteoporosis isn't just your grandmother's disease. We all need to take
better care of our bones," Dr. Carmona said. "The good news is that you are
never too old or too young to improve your bone health. With healthy nutrition,
physical activity every day, and regular medical check-ups and screenings,
Americans of all ages can have strong bones and live longer, healthier lives.
Likewise, if it's diagnosed in time, osteoporosis can be treated with new drugs
that help prevent bone loss and rebuild bone before life-threatening
fractures occur."
According to the new report, osteoporosis is a "silent" condition because
many Americans are unaware that their bone health is in jeopardy. In fact, four
times as many men and nearly three times as many women have osteoporosis than
report having the condition. One of the most dangerous myths about
osteoporosis is that only women need to worry about bone health. Osteoporosis
affects
men and women of all races, and while bone weakness manifests in older
Americans, strong bones begin in childhood.
The Surgeon General's report is a call for Americans to take action to
improve and maintain healthy bones. The report includes recommendations on what
Americans can do to decrease the likelihood of developing osteoporosis.
These recommendations include:
Getting the recommended amounts of calcium and vitamin D. High levels of
calcium can be found in milk, leafy green vegetables, soybeans, yogurt and
cheese. Vitamin D is produced in the skin by exposure to the sun and is found
in
fortified milk and other foods. For individuals who are not getting enough
calcium and vitamin D in the diet, supplements may be helpful. The average
adult
under 50 needs about 1000mg of calcium per day and 200 International Units
(IU) of Vitamin D (one cup of vitamin D fortified milk provides 302 mg of
calcium and 50 IU of Vitamin D).
Maintaining a healthy weight and being physically active at least 30 minutes
a day for adults and 60 minutes a day for children, including weight-bearing
activities to improve strength and balance.
Taking steps to minimize the risk of falls by removing items that might
cause tripping, improving lighting, and encouraging regular exercise and vision
tests to improve balance and coordination.
"I always worried about heart disease and cancer, but was never concerned
about the health of my bones," said Abby Perelman, who is being treated for
osteoporosis. "I wish I knew then what I know now -- that a healthy diet and
physical activity can make bones stronger and healthier."
The report also calls on health care professionals to help Americans
maintain healthy bones by evaluating risks for patients of all ages,
recommending
bone density tests for women over the age of 65 and for any man or woman who
suffers even a minor fracture after the age of 50. In addition, the report
calls on health care professionals to look for "red flags" that may indicate
that
someone is at risk, including people who are under 50 who have had multiple
fractures, or patients who take medications or have a disease that can lead
to bone loss.
"All health care professionals need to be aware of the early indicators of
bone disease," said Dr. Lawrence Raisz of the University of Connecticut Health
Center, one of the scientific editors of the report. "Many of my patients had
no idea their minor fracture was an indication of a larger problem. The
health care system can do a better job of helping patients protect themselves
from bone disease."
In addition to the release of the report, the Surgeon General has published
a companion "People's Piece" specifically written for the American people. The
magazine-style, full-color booklet offers ready-to-use information on how
people can improve their bone health. This is the second People's Piece that
Dr. Carmona has produced as part of his commitments to improving the health
literacy of Americans and providing the best scientific information available
in
a way that everyone can understand and use to live longer, healthier lives.
The first People's Piece discussed the health consequences of smoking and was
released in May 2004.
The free People's Piece, The 2004 Surgeon General's Report on Bone Health
and Osteoporosis: What It Means To You, is available by calling toll free
1-866-718-BONE or visiting _www.surgeongeneral.gov_
(http://www.surgeongeneral.gov)
.
"Thirty years ago, doctors thought weak bones and osteoporosis were a
natural part of aging, but today we know they are not. We can do a lot to
prevent
bone disease," said Dr. Carmona. "Everyone has a role to play in improving
bone health, and this report is a starting point for national action on bone
health. Let's get started by taking action today in homes, health care
settings,
and communities across our nation."
Source: US Department of Health & Human Services - © 1996-2004 MedicineNet,
Inc. All rights reserved.
************************************************
RESEARCHERS: STRESS CAUSES FORGETFULNESS
WASHINGTON (AP) -- How many people have gotten home after a blindingly
stressful day and realize they've forgotten some important event or errand?
Well,
now at least there's a scientific explanation for the oversight. Stress makes
you forgetful.
People going on stage or taking an exam or finding themselves in similarly
tough situations already knew this, of course.
But a team of researchers has found how it happens, a discovery that they
say could point the way to better treatments for such illnesses as schizophrenia
and bipolar disorder.
Stressful situations in which the individual has no control were found to
activate an enzyme in the brain called protein kinase C, which impairs the
short-term memory and other functions in the prefrontal cortex, the
executive-decision part of the brain, says Dr. Amy F. T. Arnsten of Yale Medical
School.
The findings were reported in the journal Science.
The PKC enzyme is also active in bipolar disorder and schizophrenia, and
Arnsten notes that a first psychotic episode can be precipitated by a stressful
situation, such as going away to college for the first time or joining the
military.
By affecting that part of the brain, the researchers say, PKC could be a
factor in the distractibility, impulsiveness and impaired judgment that occurs
in those illnesses.
The finding that uncontrolled stress activates PKC indicates a possible new
direction for treatments â seeking drugs that inhibit PKC, Arnsten said in a
telephone interview.
"These new findings may also help us understand the impulsivity and
distractibility observed in children with lead poisoning," she said. "Very low
levels
of lead can activate PKC, and this may lead to impaired regulation of
behavior."
The researchers used chemicals to induce stress in rats and monkeys because
the stress levels are easily controlled, Arnsten said.
It was similar to humans exposed to loud noise or panicking before an exam,
she said.
"It doesn't have to be traumatic, as long as you feel out of control," she
said. "Control is the essential factor. ... If you are confident, you don't
have these problems."
PKC affects a part of the brain that allows abstract reasoning, using
working memory that is constantly updated.
"This kind of memory, the ability to concentrate, seems to be impaired when
exposed to mild stresses," she said.
Scientists think the effect evolved as a protective mechanism in the event
of danger, she said.
"If you're in dangerous conditions it helps to be distractible, to hear
every little sound in the woods and react rapidly, instinctually," she said.
"It's like getting cut off on the highway. You don't want to be a slow,
thoughtful creature. ... You want to react and hit brakes."
The research was funded by the Public Health Service, the Stanley
Foundation, National Institute of Mental Health, Stanley Medical Research
Institute and
the National Alliance for Research on Schizophrenia and Depression.
Copyright 2004 The Associated Press. All rights reserved.
*******************************************************
EXPERTS: FEWER TAKE STATINS THAN SHOULD
(The Associated Press)
Perhaps no medicine today is so widely regarded as a wonder drug as the
cholesterol-lowering statin. From Zocor to Lipitor to Pravachol, statins are top
sellers in a country where half of American adults have high cholesterol.
In Britain, they recently became available over the counter, and there are
efforts afoot in the United States to do the same.
This summer, a U.S. advisory panel set recommended cholesterol levels even
lower, encouraging millions more Americans to take statins. But because all but
one member of that panel receives money from the makers of those drugs, some
consumer advocates wonder about the credibility of the latest advice.
Still, no one questions the overall value of these drugs, which quickly and
drastically lower the cholesterol that builds up in blood vessels, thus
preventing heart attacks and strokes.
The first statin, Mevacor, came on the market in 1987. Now there are five
others in the United States. About 13 million Americans take statins -- roughly
one-third of the number for whom they're recommended.
The most famous recent example is former President Bill Clinton, who was
prescribed a statin for high cholesterol when he left office several years ago
but who stopped taking it at some point. On Labor Day, he had a quadruple
bypass operation for arteries so severely clogged that doctors said he was in
grave danger of a major heart attack.
Proponents of statins, such as the National Lipid Association, a largely
industry-funded group, say Clinton's case shows the need for educating more
doctors to treat cholesterol more aggressively.
"How in the heck did he get something that could be prevented? The
president's doctors didn't even know how to manage lipids," said the group's
executive
director, Christopher Seymour.
A federally funded program, the National Cholesterol Education Program, was
formed in 1985 to help educate Americans about this risk factor. Its revised
guidelines, issued in July, have been criticized by some as perhaps too
aggressive for certain groups like the elderly, women and people with diabetes.
They advise people at high risk of a heart attack to get their level of LDL
or "bad" cholesterol to 70, instead of 100, the previous target. The
guidelines urge people at moderate-to-high risk to aim for 100 versus the
previous
target of 130.
The drugs and their makers are Merck's lovastatin (Mevacor) and simvastatin
(Zocor); Bristol-Myers Squibb's pravastatin (Pravachol); Novartis
Pharmaceuticals' fluvastatin (Lescol); Pfizer's atorvastatin (Lipitor), and
AstraZeneca's rosuvastatin (Crestor).
Side effects are very rare, but can include severe muscle weakness. The
federal Food and Drug Administration has warned doctors to be careful about
prescribing statins, particularly Crestor, in certain patients at higher risk of
complications, including certain Asians, the elderly, and people with thyroid
or kidney problems. Copyright 2004 The Associated Press. All rights reserved.
*****************************************************
MEDICARE PREMIUMS TO RISE 17 PERCENT IN 2005
Increase in payments for doctor visits is largest ever jump - The Associated
Press
WASHINGTON - Medicare premiums for doctor visits will rise 17 percent next
year, the Bush administration. The $11.60-a-month increase is the largest in
the programâs 40-year-history.
Monthly payments for Part B of the government health care program for older
and disabled Americans â doctor visits and most other non-hospital expenses
â
will jump to $78.20 from $66.60.
The premiums are updated annually under a formula set by law. The federal
government picks up about 75 percent of the cost of Part B benefits and
beneficiaries pay the rest.
The increase reflects rapidly rising health costs and last yearâs Medicare
overhaul, said Dr. Mark McClellan, administrator of the federal Centers for
Medicare and Medicaid Services. For example, the law blocked a planned 4.5
percent cut in Medicare payments to physicians and replaced it with a 1.5
percent
increase.
The administration, seeking political advantage among older voters, has
tried to depict the Medicare law, with its first-ever prescription drug benefit,
as a boon to seniors.
âThe new premiums reflect an enhanced Medicare that is providing seniors and
people with disabilities with strengthened access to physician services and
new preventive benefits,â McClellan said.
But Democrats and other critics have derided the law as a giveaway to
insurers, drug makers and medical providers.
Premiums have been increasing at an accelerating pace in recent years,
rising 13.5 percent in 2004 and 8.7 percent last year.
In addition, the deductible for Part B services will rise $10 next year, to
$110, another change mandated by the Medicare law.
About 93 percent of Medicareâs 41.8 million beneficiaries are enrolled in
Part B, which helps pay for physician services, hospital outpatient care,
durable medical equipment and other services, including some home health care.
McClellan said new preventive health services that Medicare will begin
covering in 2005, including a physical for those who become eligible for
Medicare
and screening for diabetes, will help save money for beneficiaries.
The 4.6 million people in Medicare managed care could see their
out-of-pocket expenses decline next year, he said.
âOn net, Medicare beneficiaries are saving money,â McClellan said.
The government also said the Part A portion of Medicare that pays for
hospital stays, skilled nursing facilities and some home health care also will
see
an increase in the deductible, which will rise $36 to $912 next year. It is a
Medicare recipientâs only cost for up to 60 days of inpatient hospital care.
© 2004 The Associated Press. All rights reserved.
**************************************************
Editors Note: Because of the ongoing controversy regarding all of the Cox -2
Inhibitor drugs, and what was reported in my last two newsletters, I have
decided to publish an extra issue on 12/01 pertaining solely to this subject.
There has been so much information about this recently, along with trouble and
controversy at the FDA.
If you are taking Vioxx, Celebrex, or Bextra and have Psoriatic Arthritis
along with a heart condition, please check with your Doctor.
Good Health to All,
Jack Nicholas
Newsletter Editor
_Cornishpro@..._ (mailto:Cornishpro@...)
Issue 2004 11/30/04 -17